Best PRP Hair Treatment in Pune: Everything You Need to Know Before Getting Started
October 5, 2026
No Comments
Read More »
Written by: Dr. Kiran Chotaliya Editorial Team · Reviewed by: Dr. Kiran Chotaliya, M.D. Dermatologist & Chief Hair transplant Surgeon · Hairfree & Hairgrow Clinics, India · Updated Oct 2026
This case study documents the 6-month treatment journey of a 51-year-old female patient diagnosed with alopecia areata. Before treatment, the patient presented with marked thinning across the frontal, central, and upper scalp, resulting in significant scalp visibility and reduced overall hair coverage.
According to the supplied patient information, there was no significant medical history, and the treatment plan consisted of Kenacort Injection for alopecia areata. Serial photographs document visible progress at approximately 1, 3, 5, and 6 months.
The case study below follows the same structure and level of detail as the supplied reference document, including patient profile, clinical assessment, treatment plan, month-wise progress, outcome, aftercare, disclaimer, and FAQs. Pasted markdown
Patient Consent Notice
This case study has been published with the patient’s informed consent for educational and informational purposes. Appropriate measures have been taken to maintain patient privacy while documenting the scalp condition, treatment process, and visible follow-up progress.
Individual outcomes with alopecia areata treatment can vary. Hair regrowth may depend on the extent and activity of the condition, duration of hair loss, individual biological response, recurrence, and response to prescribed treatment.
The result shown in this case should not be considered a guarantee of similar outcomes for every patient.
Patient Details | Information |
Age | 51 years |
Gender | Female |
Diagnosis | Alopecia Areata |
Medical History | No significant medical history reported |
Initial Condition | Marked scalp thinning with significant scalp exposure |
Affected Area | Frontal, central and upper scalp |
Treatment Plan | Kenacort Injection |
Treatment Type | Intralesional corticosteroid treatment |
Documented Follow-Up | 1, 3, 5 and 6 months |
Latest Documented Progress | 6 months |
Before beginning treatment, the clinical photographs showed marked thinning across a large portion of the frontal and upper scalp.
The pretreatment condition included:
The pretreatment photographs served as the baseline against which subsequent improvement was assessed.
The patient was clinically evaluated according to the distribution and severity of scalp hair loss.
Assessment focused on:
Serial photographs were used to monitor visible progress, consistent with the follow-up approach used in the supplied reference format. Pasted markdown
|
Parameter
|
No. of Grafts
|
Details
|
|---|---|---|
|
|
530
|
For natural hairline
|
|
|
2480
|
Mid scalp coverage
|
|
|
3010
|
|
Following clinical assessment, the patient was advised Kenacort Injection treatment for alopecia areata.
Kenacort contains triamcinolone, a corticosteroid that may be administered intralesionally by dermatologists in selected alopecia areata cases. The concentration, amount, treatment interval, injection sites, and number of sessions should be determined individually by the treating dermatologist according to clinical findings and treatment response. Pasted markdown
The treatment plan focused on:
Kenacort Injection was administered according to the dermatologist’s individualized treatment plan.
Treatment was directed toward the affected areas of the scalp based on clinical assessment.
Follow-up monitoring included:
The photographic sequence demonstrates that visible improvement developed progressively over several months rather than immediately, similar to the pattern described in the reference case. Pasted markdown
Before treatment, the patient showed marked thinning and significant visible scalp exposure, especially over the frontal and central scalp.
The photographs demonstrated:
This served as the baseline for subsequent comparison.
At approximately 1 month, the overall scalp appearance remained similar to baseline.
The photographs showed:
This represented a very early treatment stage and should not be interpreted as the final outcome.
At the 3-month follow-up, visible improvement in coverage had begun.
Compared with baseline:
This stage indicated developing regrowth and improved coverage, although further maturation was still expected.
By approximately 5 months, the patient’s photographs showed more noticeable improvement.
Visible observations included:
The difference from the pretreatment stage was increasingly apparent.
At the 6-month follow-up, the patient showed substantial visible improvement compared with the baseline photographs.
The photographs demonstrate:
A central parting remained visible, but the width and prominence of the exposed scalp appeared considerably reduced compared with the pretreatment condition.
The 6-month stage represents the latest documented follow-up, rather than a guaranteed permanent or final result.
At the 6-month follow-up, the patient showed substantial visible improvement compared with the baseline photographs.
The photographs demonstrate:
A central parting remained visible, but the width and prominence of the exposed scalp appeared considerably reduced compared with the pretreatment condition.
The 6-month stage represents the latest documented follow-up, rather than a guaranteed permanent or final result.
Following Kenacort Injection treatment, the patient should continue dermatologist-directed follow-up and scalp care.
Recommended maintenance may include:
Long-term follow-up helps determine whether further treatment is necessary and whether regrowth remains stable. Pasted markdown
Treatment Stage | Observed Progress |
Before Treatment | Marked frontal and upper scalp thinning with significant scalp exposure |
1 Month | Early stage with persistent visible thinning and limited density change |
3 Months | Developing hair coverage with reduced scalp exposure in some regions |
5 Months | Progressive improvement in frontal and central scalp density |
6 Months | Latest documented stage with considerably improved coverage and reduced scalp visibility |
Long-term dermatologist-directed monitoring remains important because alopecia areata can have an unpredictable course.
General aftercare may include:
The supplied reference case similarly emphasizes ongoing clinical monitoring and avoiding unsupervised changes to corticosteroid treatment. Pasted markdown
The patient’s documented treatment plan included Kenacort Injection for alopecia areata, administered according to the dermatologist’s clinical assessment.
Kenacort contains triamcinolone, a corticosteroid. Intralesional corticosteroid treatment may be used by dermatologists in selected alopecia areata cases. The concentration, dose, injection sites, and treatment intervals should be individualized.
The photographs show that visible improvement became more noticeable around the 3-month follow-up, with continued improvement at 5 and 6 months.
Dr. Kiran Chotaliya is a leading hair transplant surgeon in Pune, specializing in advanced techniques like FUE and FUT for natural, lasting results. His expertise and patient-centered care ensure successful hair restoration with exceptional outcomes.
© 2026 Developed & Handle By Dr. Kiran Chotaliya Clinic Team
© 2026 Developed & Handle By Dr. Kiran Chotaliya Clinic Team